Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brivaracetam in Patients With Diffuse Gliomas
NCT05029960Phase 1Terminated
- Sponsor
- University of Rochester
- Start
- May 2022
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of brivaracetam in Diffuse Glioma (DG), sponsored by University of Rochester. Primary endpoint: Safety of Brivaracetam at 6 months. Started May 2022; status: terminated.
02
Drugs
brivaracetam
03
Conditions
Diffuse Glioma (DG)
Beyond the preview
Go deeper on NCT05029960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05029960.